An online frenzy over a new SMA gene therapy
Zolgensma, the Novartis gene therapy for spinal muscular atrophy, caused quite the furor over the weekend. The newly approved therapy is a lifesaving treatment for a fatal condition. On Friday its price tag was also, ahem, pegged at $2.1 million. (An eye-popping figure that can easily distract from discussions of value and commercial justification and annualized costs.)
Frustration over the focus on price and a debate over exactly how to cast the news led to some important questions — and hilarious reactions — in the Twittersphere.
So STAT's Matt Herper challenged his followers to come up with alternative headlines for the therapy's approval that didn't center on the price tag. Here were some of the responses:
Frustration over the focus on price and a debate over exactly how to cast the news led to some important questions — and hilarious reactions — in the Twittersphere.
So STAT's Matt Herper challenged his followers to come up with alternative headlines for the therapy's approval that didn't center on the price tag. Here were some of the responses:
New drug saves dying kids — yet many people are peeved -@dewdiligence
Novartis reduces price of being born with SMA, despite $2.1M treatment. -@amitabchandra2
Most Expensive drug in history still cheaper than buying apartment in San Francisco; cures babies. Maybe. -@keithcspencer
And John Arnold, the billionaire former hedge fund guy and founder of the eponymous Arnold Foundation, made a smart point:
Most Expensive drug in history still cheaper than buying apartment in San Francisco; cures babies. Maybe. -@keithcspencer
And John Arnold, the billionaire former hedge fund guy and founder of the eponymous Arnold Foundation, made a smart point:
.png)
No hay comentarios:
Publicar un comentario